Powered By Purpose

2021 Business Results
February 3, 2022

AGENDA

INTRODUCTION AND KEY RECENT EVENTS

Dave Ricks, Chair and Chief Executive Officer

Q4 2021 FINANCIAL RESULTS

Anat Ashkenazi, Chief Financial Officer

R&D UPDATE

Dan Skovronsky, M.D., Ph.D., Chief Scientific and Medical Officer

CLOSING REMARKS

Dave Ricks, Chair and Chief Executive Officer

QUESTION AND ANSWER SESSION

SAFE HARBOR PROVISION

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K,10-Q, and any 8-Ks filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP.

The company undertakes no duty to update forward-looking statements except as required by applicable law

STRATEGIC DELIVERABLES

PROGRESS SINCE THE LAST EARNINGS CALL

Grow Revenue

- 15% revenue growth FY; 10% growth excluding COVID-19 antibodies*
- 8% revenue growth in Q4; 6% growth excluding COVID-19 antibodies*
- Q4 revenue growth driven by:
  - 11% volume growth
  - Key growth products, which accounted for 61% of core business revenue

Improve Productivity

- Non-GAAP gross margin
  - 76.1% in Q4 (76.2% excluding FX impact on international inventories sold)
  - 77.4% FY (78.2% excluding FX impact on international inventories sold)
- Non-GAAP operating margin
  - 31.7% in Q4, 130 basis points lower than prior year
  - 29.9% FY, 30 basis points higher than prior year

Create Long-Term Value

- Announced planned manufacturing investments of more than $1 billion for a new site in North Carolina and more than €400 million for a new site in Ireland
- Distributed nearly $800 million via dividends in Q4
- Completed $750 million in share repurchases in Q4
- Announced a 15% dividend increase for 2022

Speed Life-Changing Medicines

- Positive results from a Phase 3 maintenance trial of **mirikizumab** in ulcerative colitis
- Positive results from a third **lebrikizumab** Phase 3 trial when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis after 16 weeks
- Initiated a rolling submission to the FDA for **pirtobrutinib**, seeking accelerated approval in mantle cell lymphoma
- Submitted **Bebtelovimab** to the FDA for Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

*Sales for COVID-19 antibodies include bamlanivimab and etesevimab sold pursuant to Emergency Use Authorization

KEY EVENTS SINCE THE LAST EARNINGS CALL

REGULATORY

- The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) and granted Priority Review for **Jardiance®** as a potential new treatment to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure independent of left ventricular ejection fraction (LVEF);
- The FDA granted Breakthrough Therapy designation for **N3pG 4** as an investigational treatment for early Alzheimer's disease. Lilly plans to start pivotal trials by the end of 2022;
- **Tirzepatide** submissions were accepted by the FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, for the treatment of adults with type 2 diabetes. A Priority Review Voucher was applied to FDA submission; and
- Initiated a rolling submission to the FDA for **pirtobrutinib**, seeking accelerated approval in mantle cell lymphoma, with expectations to complete the submission in 2022 and receive regulatory action in early 2023; and
- Lilly is in ongoing discussion with the FDA regarding the status of the sNDA for **Olumiant®** for the treatment of adults with moderate-to-severe atopic dermatitis. At this point, the company does not have alignment with the FDA on the indicated population. Given the Agency's position, there is a possibility that this could lead to a Complete Response Letter (CRL).

CLINICAL

- Based on top-line efficacy results from two pivotal Phase 3 trials (SLE-BRAVE-I and –II), the company has decided to discontinue the Phase 3 development program for **Olumiant** in adults with active systemic lupus erythematosus;
- **Lebrikizumab** significantly improved disease severity when combined with TCS in people with moderate-to-severe atopic dermatitis (AD) in a third pivotal Phase 3 trial, meeting all primary and key secondary endpoints for patients on the lebrikizumab combination arm; and
- **Mirikizumab** met the primary endpoint of clinical remission and all key secondary endpoints at one year in a Phase 3 maintenance study for the treatment of patients with moderately-to-severely active ulcerative colitis (UC), building on the positive outcomes from a 12-week induction study.

BUSINESS DEVELOPMENT

- Announced a multi-year research collaboration and licensing agreement with **QILU Regor Therapeutics Inc.** to discover, develop and commercialize novel therapies for metabolic disorders;
- Announced a strategic collaboration to create novel oncology medicines by applying **Foghorn Therapeutics Inc.'s** proprietary Gene Traffic Control® platform; and

Note: Jardiance is part of the Boehringer Ingelheim (BI) and Lilly Alliance, and BI holds the marketing authorization for Jardiance

KEY EVENTS SINCE THE LAST EARNINGS CALL

BUSINESS DEVELOPMENT (CONT)

- Acquired exclusive rights to **Entos Pharmaceuticals Inc.'s** Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system.

COVID-19

- The U.S. government signed a purchase agreement for 614,000 additional doses of **bamlanivimab and etesevimab** for a total of $1.29 billion. There were approximately 435,000 doses delivered in the fourth quarter of 2021 with most of the remaining doses already shipped in January 2022;
- The FDA expanded the Emergency Use Authorization (EUA) for **bamlanivimab and etesevimab** administered together to include certain high-risk pediatric patients from birth to <12 years old;
- The FDA has updated the Fact Sheet for **bamlanivimab and etesevimab** to include a new Limitation for Authorized Use. Due to the high frequency of the Omicron variant, these therapies are not currently authorized in any U.S. region;
- The FDA accepted a sNDA and granted Priority Review for **Olumiant (baricitinib)**. Olumiant has an EUA for the treatment of COVID-19 in hospitalized adults and pediatric patients 10 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and

COVID-19 (CONT)

- **Bebtelovimab** was submitted to the FDA for EUA for the treatment of mild-to-moderate COVID-19 for patients at high risk for progression to severe COVID-19, including hospitalization or death. Bebtelovimab retained neutralization against Omicron and all other known variants of concern.

OTHER

- Announced a 15% dividend increase for 2022;
- Announced plans to invest more than $1 billion to create a **new manufacturing site in North Carolina** that will utilize innovative technology to manufacture injectable products and devices and increase the company's manufacturing capacity; and
- Announced plans to invest more than €400 million in a **new manufacturing site in Ireland** to expand Lilly's manufacturing network for biologic active ingredients, support increased demand for existing Lilly products and new pipeline, including its promising Alzheimer's portfolio.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

	Q4 2021			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	Non-GAAP Adjusted Change
TOTAL REVENUE	**$8,000**	-	**$8,000**	8%
GROSS MARGIN	**74.4%**	1.7%	**76.1%**	(2.5)pp
TOTAL OPERATING EXPENSE	**4,033**	(482)	**3,551**	5%
OPERATING INCOME	**1,917**	619	**2,536**	3%
OPERATING MARGIN	**24.0%**	7.7%	**31.7%**	(1.3)pp
OTHER INCOME (EXPENSE)	**(77)**	70	**(7)**	78%
EFFECTIVE TAX RATE	**6.2%**	4.1%	**10.3%**	(2.8)pp
NET INCOME	**$1,726**	$542	**$2,268**	8%
EPS	**$1.90**	$0.59	**$2.49**	8%

Note: Numbers may not add due to rounding; see slide 24 for a complete list of significant adjustments.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

	FY 2021			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	Non-GAAP Adjusted Change
TOTAL REVENUE	**$28,318**	-	**$28,318**	15%
GROSS MARGIN	**74.2%**	3.2%	**77.4%**	(1.9)pp
TOTAL OPERATING EXPENSE	**14,649**	(1,191)	**13,458**	10%
OPERATING INCOME	**6,357**	2,100	**8,457**	16%
OPERATING MARGIN	**22.4%**	7.5%	**29.9%**	0.3pp
OTHER INCOME (EXPENSE)	**(202)**	227	**26**	NM
EFFECTIVE TAX RATE	**9.3%**	3.0%	**12.3%**	(0.7)pp
NET INCOME	**$5,582**	$1,855	**$7,437**	20%
EPS	**$6.12**	$2.04	**$8.16**	20%

Note: Numbers may not add due to rounding; see slide 25 for a complete list of significant adjustments.

PRICE/RATE/VOLUME EFFECT ON REVENUE

Millions

	Q4 2021					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$5,176	(2)%	-	14%	13%	13%
EUROPE	1,147	(3)%	(1)%	(0)%	(5)%	(3)%
JAPAN	535	(2)%	(6)%	(11)%	(19)%	(14)%
CHINA	376	(30)%	4%	44%	17%	13%
REST OF WORLD	765	(3)%	1%	19%	17%	16%
TOTAL REVENUE	$8,000	(3)%	(0)%	11%	8%	8%

	FY 2021					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$16,811	(1)%	-	19%	18%	18%
EUROPE	4,777	(2)%	5%	11%	14%	9%
JAPAN	2,367	(2)%	(2)%	(5)%	(8)%	(6)%
CHINA	1,661	(20)%	8%	61%	49%	41%
REST OF WORLD	2,702	(3)%	2%	12%	12%	9%
TOTAL REVENUE	$28,318	(2)%	1%	16%	15%	14%

Note: Numbers may not add due to rounding

CER = price change + volume change

KEY PRODUCTS DRIVING WW VOLUME GROWTH

Contribution to 11% Q4 WW Volume Growth



Numbers may not add due to rounding

* includes Cyramza®, Emgality®, Jardiance, Olumiant, Retevmo®, Taltz®, Trulicity®, Tyvyt®, and Verzenio®

** includes bamlanivimab and etesevimab for the treatment of COVID-19 sold pursuant to Emergency Use Authorization

*** Other LOE: loss of exclusivity; includes Axiron®, Cialis®, Cymbalta®, Effient®, Evista®, Strattera®, and Zyprexa®

Jardiance is part of the Boehringer Ingelheim (BI) and Lilly Alliance

UPDATE ON KEY GROWTH PRODUCTS



RETEVMO
- Growth driven by indications in advanced RET lung and thyroid cancer

TYVYT
- Continued PD-1 penetration in China

EMGALITY
- U.S. NBRx SOM nearly 44% at end of Q4 2021 (injectable CGRP)
- U.S. TRx SOM nearly 39%

VERZENIO
- U.S. TRx grew 43% vs. Q4 2020, outpacing the market
- Launch in certain people with high-risk early breast cancer

OLUMIANT
- OUS sales grew 30% vs. Q4 2020

TALTZ
- IL-17 dermatology leader in U.S. TRx SOM 20%
- U.S. TRx grew nearly 36% vs. Q4 2020, outpacing the market

JARDIANCE
- Market leader in U.S. TRx SOM nearly 61% at end of Q4 2021
- U.S. TRx grew 31% vs Q4 2020, outpacing the market

CYRAMZA
- WW sales slightly declining vs Q4 2020

TRULICITY
- Market leader in U.S. TRx SOM nearly 48% (injectable GLP-1)
- U.S. TRx grew 35% vs Q4 2020, outpacing the market

Note: Jardiance is sold by Boehringer Ingelheim; Lilly records as revenue its share of Jardiance gross margin; Jardiance is part of the Boehringer Ingelheim and Lilly Alliance

CAPITAL ALLOCATION

Billions



* After-tax
** Includes cash outflows associated with equity investments

2022 GUIDANCE

	Prior	Updated	Comments
TOTAL REVENUE	$27.8 – $28.3 billion	unchanged	
GROSS MARGIN % (GAAP)	Approx. 78%	unchanged	
GROSS MARGIN % (NON-GAAP)	Approx. 80%	unchanged	
MKTG, SELLING & ADMIN.	$6.4 – $6.6 billion	unchanged	
RESEARCH & DEVELOPMENT	$7.0 – $7.2 billion	unchanged	
OTHER INCOME/(EXPENSE)	$(100) – $0 million	unchanged	
TAX RATE	Approx. 13 – 14%	unchanged	
EARNINGS PER SHARE (GAAP)	$8.00 – $8.15	unchanged	
EARNINGS PER SHARE (NON-GAAP)	$8.50 – $8.65	unchanged	
OPERATING INCOME % (GAAP)	Approx. 30%	unchanged	
OPERATING INCOME % (NON-GAAP)	Approx. 32%	unchanged	

2022 assumes GAAP and non-GAAP shares outstanding of 908 million

Updated FX assumptions of 1.17 (Euro), 112 (Yen) and 6.50 (Renminbi)

LILLY SELECT NME AND NILEX PIPELINE

JANUARY 31, 2022

PHASE 1

- CD19 ANTIBODY — Immunology
- RELAXIN-LA — Heart Failure
- RIPK1 INHIBITOR — Immunology
- BCL2 (LOXO-338) — Cancer
- OXYNTOMODULIN — Diabetes
- P2X7 INHIBITOR — Pain
- PYY ANALOG — Diabetes
- N3pG 4 — Alzheimer's
- NOT DISCLOSED — Diabetes
- NRG4 AGONIST — Heart Failure
- KRAS G12C II — Cancer
- LP(a) INHIBITOR — CVD
- LP(a) siRNA — CVD
- GIPR AGONIST LA II — Diabetes
- IDH1 INHIBITOR — Cancer
- KHK INHIBITOR II — Diabetes / NASH
- CD200R MAB AGONIST — Immunology
- GIP/GLP COAGONIST PEPTIDE — Diabetes
- GIPR AGONIST LA — Diabetes
- ANGPTL3 siRNA — CVD
- AUR A KINASE INHIBITOR — Cancer
- BTLA MAB AGONIST — Immunology

PHASE 2

- PIRTOBRUTINIB — B-Cell Malignancies
- TIRZEPATIDE — NASH
- GLP-1R NPA — Obesity
- IL-2 CONJUGATE — Ulcerative Colitis
- GBA1 GENE THERAPY — Gaucher Disease Type 2
- GGG TRI-AGONIST — Obesity
- O-GLCNACASE INH — Alzheimer's
- PIRTOBRUTINIB^^ — R/R MCL (Prior BTK)
- SSTR4 AGONIST — Pain
- TRPA1 ANTAGONIST — Pain
- PACAP38 MAB — Migraine
- PD-1 MAB AGONIST — Rheumatoid Arthritis
- IL-2 CONJUGATE — Systemic Lupus Erythematosus
- MEVIDALEN — Symptomatic LBD
- GGG TRI-AGONIST — Diabetes
- GLP-1R NPA — Diabetes
- GBA1 GENE THERAPY — Parkinson's Disease
- GRN GENE THERAPY — Frontotemporal Dementia
- CXCR1/2L MAB — Hidradenitis Suppurativa
- EPIREG/TGFα MAB — Chronic Pain
- AUTOMATED INSULIN DELIVERY SYS — Diabetes
- BASAL INSULIN-FC — Diabetes

PHASE 3

- PIRTOBRUTINIB — 1L CLL
- SELPERCATINIB — Adjuvant RET+ NSCLC
- TIRZEPATIDE — Obesity
- DONANEMAB — Preclinical Alzheimer's
- TIRZEPATIDE — CV Outcomes
- TIRZEPATIDE — Heart Failure pEF
- SELPERCATINIB — 1L Med Thyroid Cancer
- SELPERCATINIB — 1L NSCLC
- PIRTOBRUTINIB — R/R CLL Monotherapy
- PIRTOBRUTINIB — R/R MCL Monotherapy
- MIRIKIZUMAB — Crohn's Disease
- PIRTOBRUTINIB — R/R CLL Combination
- EMPAGLIFLOZIN* — Chronic Kidney Disease
- EMPAGLIFLOZIN* — Post MI
- SOLANEZUMAB — Preclinical AD
- ABEMACICLIB — Prostate Cancer
- LEBRIKIZUMAB — Atopic Dermatitis
- MIRIKIZUMAB — Ulcerative Colitis
- DONANEMAB^^ — Early Alzheimer's
- IMLUNESTRANT — ER+ HER2- mBC

REG REVIEW

- EMPAGLIFLOZIN* — Heart Failure pEF
- CONNECTED CARE PREFILLED INSULIN PEN — Diabetes
- BARICITINIB — Alopecia Areata
- BEBTELOVIMAB (LY-CoV1404 MAB) — COVID-19
- TIRZEPATIDE — Diabetes
- SINTILIMAB (US)* — NonSquam NSCLC 1L

APPROVED

LEGEND

- NME
- NILEX
- * Commercial Collaboration
- *MOVEMENT SINCE October 22, 2021*
- ADDITION or MILESTONE ACHIEVED
- REMOVAL
- ◈ Reflects submission for Emergency Use Authorization in the US
- ^^ Rolling submission in the U.S. initiated

- IL-17A SMALL MOL INHIBITOR — Immunology

- ABEMACICLIB — HER2+ Early BC
- BARICITINIB — Systemic Lupus Erythematosus

KEY EVENTS 2021

New since last update

Phase 3 Initiations

- **Abemaciclib** for HR+, HER2+ early breast cancer
- **Abemaciclib** for prostate cancer
- **Pirtobrutinib** for MCL monotherapy
- **Pirtobrutinib** for CLL monotherapy
- **Pirtobrutinib** for CLL combination therapy
- **Pirtobrutinib** for CLL first-line
- **Tirzepatide** for obesity (3 additional studies)
- **Tirzepatide** for HFpEF
- **Donanemab** for asymptomatic Alzheimer's disease
- **Imlunestrant** for metastatic breast cancer
- **Donanemab** plaque clearance head-to-head

Phase 3 & Other Key Data Disclosures

- **Baricitinib** for alopecia areata
- **Baricitinib** for systemic lupus erythematosus
- **Donanemab** for early Alzheimer's disease
- **Empagliflozin** for HFpEF[1]
- **Lebrikizumab** for atopic dermatitis
- **Mirikizumab** for ulcerative colitis (induction data)
- **Mirikizumab** for ulcerative colitis (maintenance data)
- **Tirzepatide** for type 2 diabetes (SURPASS-2)
- **Tirzepatide** for type 2 diabetes (SURPASS-3)
- **Tirzepatide** for type 2 diabetes (SURPASS-4)
- **Tirzepatide** for type 2 diabetes (SURPASS-5)
- **Zagotenemab** for early Alzheimer's disease

Medical Meeting Presentations

- **Donanemab** for early Alzheimer's disease
- **Imlunestrant** for metastatic breast cancer
- **Tirzepatide** for type 2 diabetes (SURPASS 1 / 2 / 3 / 4 / 5)
- **Pirtobrutinib** additional data for Phase 1/2 Study

Regulatory Submissions

- **Abemaciclib** for high-risk HR+, HER2- early breast cancer (J)
- **Baricitinib** for alopecia areata (US / EU /J)
- **Bamlanivimab + Etesevimab** for COVID-19 (EU / US[2])
- **Sintilimab** for NSCLC (US)
- **Tirzepatide** for type 2 diabetes (US /EU / J)
- **Empagliflozin** for HFpEF[1] (US /EU / J)

Regulatory Actions

- **Abemaciclib** for high-risk HR+, HER2- early breast cancer (US /EU/ J)
- **Baricitinib** for atopic dermatitis (J)
- **Baricitinib** for COVID-19 (J)
- **Empagliflozin** for HFrEF (US /EU / J)[1]
- **Selpercatinib** for NSCLC and thyroid cancers (EU / J)[3]
- **Tanezumab** for osteoarthritis pain (US)[4]
- **Bamlanivimab + Etesevimab** EUA for COVID-19

[1] in collaboration with Boehringer Ingelheim
[2] not proceeding forward with BLA
[3] Japan approval in NSCLC
[4] in collaboration with Pfizer

POTENTIAL KEY EVENTS 2022

New since last update

Phase 3 Initiations

- **Basal Insulin-Fc** for type 2 diabetes (QWINT-1)
- **Basal Insulin-Fc** for type 2 diabetes (QWINT-2)
- **Basal Insulin-Fc** for type 2 diabetes (QWINT-3)
- **Basal Insulin-Fc** for type 2 diabetes (QWINT-4)
- **Basal Insulin-Fc** for type 1 diabetes (QWINT-5)
- **N3PG 4** for early Alzheimer's disease
- **Pirtobrutinib** for CLL BTKi naïve H2H vs ibrutinib
- **Tirzepatide** for morbidity/mortality in obesity (SURMOUNT-MMO)
- **Tirzepatide** for obstructive sleep apnea (SURMOUNT-OSA)

Phase 3 & Other Key Data Disclosures

- **Donanemab** for plaque clearance in early AD (H2H vs aducanumab)
- **Empagliflozin** for chronic kidney disease
- **Galcanezumab** for episodic migraine (H2H vs rimegepant)
- **Lebrikizumab** for atopic dermatitis (maintenance data)
- **Tirzepatide** for obesity (SURMOUNT-1)

Medical Meeting Presentations

- **Lebrikizumab** for atopic dermatitis
- **Mirikizumab** for ulcerative colitis

Regulatory Submissions

- **Bebtelovimab** EUA for COVID-19
- **Donanemab** for early Alzheimer's disease[1]
- **Lebrikizumab** for atopic dermatitis
- **Mirikizumab** for ulcerative colitis
- **Pirtobrutinib** for MCL prior BTKi[1]
- **Selpercatinib** for metastatic tumor agnostic RET fusion+

Regulatory Actions

- **Bebtelovimab** EUA for COVID-19
- **Abemaciclib** for high-risk HR+, HER2- early breast cancer (EU)
- **Baricitinib** for atopic dermatitis (US[2])
- **Baricitinib** for alopecia areata (US/EU/J)
- **Donanemab** for early Alzheimer's disease (US)
- **Empagliflozin** for HFpEF (US/EU/J)[3]
- **Selpercatinib** for metastatic RET fusion-positive NSCLC (US)[4]
- **Sintilimab** for 1L NSCLC (US)
- **Tirzepatide** for type 2 diabetes (US /EU/J)

[1] Initiated rolling U.S. submission
[2] Do not have alignment with the FDA on the indicated population; could lead to a CRL
[3] In collaboration with Boehringer Ingelheim
[4] Full NDA approval

2021 PERFORMANCE SUMMARY

- **Volume-driven revenue growth** of 10% excluding COVID-19 antibodies, with key growth products comprising 57% of core business revenue
- **Operating margin of nearly 30%** in line with guidance
- Progress on our **innovation-based strategy** that delivered positive Phase 3 data on five molecules (tirzepatide, donanemab, pirtobrutinib, mirikizumab and lebrikizumab); also launched and submitted key new indications for several products including Verzenio and Jardiance
- Deployed $4.35 billion to shareholders via the dividend and share repurchases

Grow Revenue

Expect to deliver top-tier revenue growth

Improve Productivity

Non-GAAP operating margin expansion to the mid-to-high 30%s

Speed Life-Changing Medicines

- Potential to launch 20+ new molecules in 10 years (2014-2023)
- On average, could launch 2+ new indications or line extensions per year

Create Long-Term Value

- Fund existing marketed and pipeline products
- Bolster growth prospects via business development
- Annual dividend increases

SUPPLEMENTARY SLIDES

2021 INCOME STATEMENT – REPORTED

Millions; except per share data

	Q4 2021	Change	FY 2021	Change
TOTAL REVENUE	$8,000	8%	$28,318	15%
GROSS MARGIN	74.4%	(2.5)pp	74.2%	(3.5)pp
TOTAL OPERATING EXPENSE*	4,033	8%	14,649	13%
OPERATING INCOME	1,917	(4)%	6,357	5%
OPERATING MARGIN	24.0%	(2.8)pp	22.4%	(2.2)pp
OTHER INCOME (EXPENSE)	(77)	NM	(202)	NM
EFFECTIVE TAX RATE	6.2%	(8.1)pp	9.3%	(5.0)pp
NET INCOME	$1,726	(18)%	$5,582	(10)%
EARNINGS PER SHARE	$1.90	(18)%	$6.12	(10)%

* Includes research and development expense, marketing, selling and administrative expense, acquired in-process research and development charges, and asset impairment, restructuring and other special charges.
NM – not meaningful

NON-GAAP GROSS MARGIN % OF REVENUE



Individual quarter GM % of Revenue:												
with FX effect on int'l inv sold	80.2%	81.0%	79.6%	79.9%	80.3%	79.6%	79.1%	78.6%	75.4%	79.3%	79.0%	76.1%
w/o FX effect on int'l inv sold	80.2%	80.2%	78.9%	79.6%	80.6%	79.1%	79.9%	79.1%	78.0%	79.7%	79.3%	76.2%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.

NON-GAAP OPERATING MARGIN % OF REVENUE



Individual quarter Op. Margin % of Revenue:												
with FX effect on int'l inv sold	26.2%	27.9%	28.6%	26.3%	30.1%	28.0%	26.2%	33.0%	27.5%	29.4%	30.5%	31.7%
w/o FX effect on int'l inv sold	26.2%	27.2%	27.9%	25.9%	30.4%	27.5%	27.0%	33.5%	30.1%	29.9%	30.7%	31.8%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.

EFFECT OF FX ON 2021 RESULTS

Year-on-Year Growth

REPORTED	Q4 2021		FY 2021	
	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	8%	8%	15%	14%
COST OF SALES	19%	22%	33%	29%
GROSS MARGIN	4%	4%	10%	10%
OPERATING EXPENSE	8%	8%	13%	12%
OPERATING INCOME	(4)%	(4)%	5%	6%
EARNINGS PER SHARE	(18)%	(18)%	(10)%	(9)%

NON-GAAP	Q4 2021		FY 2021	
	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	8%	8%	15%	14%
COST OF SALES	20%	23%	26%	22%
GROSS MARGIN	4%	4%	13%	12%
OPERATING EXPENSE	5%	5%	10%	9%
OPERATING INCOME	3%	3%	16%	17%
EARNINGS PER SHARE	8%	8%	20%	21%

EPS RECONCILIATION

	Q4 2021	Q4 2020	% Change	FY 2021	FY 2020	% Change
EPS (REPORTED)	**$1.90**	**$2.32**	**(18)%**	**$6.12**	**$6.79**	**(10)%**
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT	.33	.35	-	.77	.64	-
AMORTIZATION OF INTANGIBLE ASSETS	.19	.11	-	.53	.36	-
ASSET IMPAIRMENT, RESTUCTURING AND OTHER SPECIAL CHARGES	.09	(.03)	-	.28	.14	-
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	.06	(.44)	-	(.16)	(1.15)	-
COVID-19 ANTIBODIES INVENTORY CHARGE	(.07)	-	-	.25	-	-
CHARGE RELATED TO REPURCHASE OF HIGHER-COST DEBT	-	-	-	.35	-	-
EPS (NON-GAAP)	**$2.49**	**$2.31**	**8%**	**$8.16**	**$6.78**	**20%**

Note: Numbers may not add due to rounding; see slides 24 and 25 for more details on these significant adjustments.

Q4 2021 INCOME STATEMENT NOTES

Q4 2021 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- costs associated with upfront payments for acquired in-process research and development projects acquired in transactions other than a business combination, related to business development transactions with Foghorn Therapeutics Inc., QILU Regor Therapeutics Inc. and Entos Pharmaceuticals Inc. totaling $376.6 million (pretax), or $0.33 per share (after-tax);
- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $219.9 million (pretax), or $0.19 per share (after-tax);
- charges primarily related to impairment of a contract-based intangible asset from the acquisition of Loxo Oncology totaling $104.5 million (pretax), or $0.09 per share (after-tax);
- net losses on investments in equity securities totaling $70.6 million (pretax), or $0.06 per share (after-tax); and
- a charge related the partial reversal of a COVID-19 antibodies inventory charge totaling $82.5 million (pretax), or ($0.07) per share (after-tax).

Q4 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- costs associated with upfront payments for acquired in-process research and development projects acquired in transactions other than a business combination, related to business development transactions with Innovent Biologics, Inc., Disarm Therapeutics, Inc. and Fochon Pharmaceuticals, Ltd. totaling $366.3 million (pretax), or $0.35 per share (after-tax);
- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $127.3 million (pretax), or $0.11 per share (after-tax);
- other specified items, primarily adjustments to prior period estimates for asset impairment and severance costs totaling $30.1 million (pre-tax), or ($0.03) per share (after-tax); and
- net gains on investments in equity securities totaling $508.0 million (pretax), or ($0.44) per share (after-tax).

FY 2021 INCOME STATEMENT NOTES

FY 2021 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination, related to business development transactions with Foghorn Therapeutics Inc., Rigel Pharmaceuticals, Inc., Precision Biosciences, Inc., Protomer Technologies Inc., Kumquat Biosciences Inc., Merus N.V., Lycia Therapeutics, Inc., QILU Regor Therapeutics Inc., Entos Pharmaceuticals Inc., ProQR Therapeutics N.V., MiNA Therapeutics Limited and Asahi Kasei Pharma Corporation totaling $874.9 million (pretax), or $0.77 per share (after-tax);
- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $614.9 million (pretax), or $0.53 per share (after-tax);
- an intangible asset impairment resulting from the sale of the rights to QBREXZA, impairment of a contract-based intangible asset from the acquisition of Loxo Oncology and acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc. totaling $316.1 million (pretax), or $0.28 per share (after-tax);
- a charge related to the repurchase of debt totaling $405.2 million (pretax), or $0.35 per share (after-tax);
- net charges resulting from inventory related to COVID-19 antibodies, totaling $293.9 million (pretax), or $0.25 per share (after-tax); and
- net gains on investments in equity securities totaling $178.0 million (pretax), or ($0.16) per share (after-tax).

FY 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination, related to both a business development transaction with a preclinical stage company as well as business development transactions with Sitryx Therapeutics Limited, AbCellera Biologics Inc., Evox Therapeutics Limited, Shanghai Junshi Biosciences Co., Ltd., Innovent Biologics Inc., Disarm Therapeutics, Inc. and Fochon Pharmaceuticals, Ltd. totaling $660.4 million (pretax), or $0.64 per share (after-tax);
- amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties totaling $411.0 million (pretax), or $0.36 per share (after-tax);
- asset impairment, restructuring and other special charges, primarily severance costs incurred related to restructuring, as well as acquisition and integration costs related to the closing of the acquisition of Dermira, Inc. totaling $131.2 million (pretax), or $0.14 per share (after-tax); and
- net gains on investments in equity securities totaling $1,323 million (pretax), or ($1.15) per share (after-tax).

COMPARATIVE EPS SUMMARY 2020/2021

	1Q20	2Q20	3Q20	4Q20	2020	1Q21	2Q21	3Q21	4Q21	2021
Reported	1.60	1.55	1.33	2.32	6.79	1.49	1.53	1.22	1.90	6.12
Non-GAAP	1.61	1.45	1.41	2.31	6.78	1.87	1.87	1.94	2.49	8.16

Note: Numbers may not add due to rounding.

For a complete reconciliation to reported earnings, see slide 23 and our earnings press release dated February 3, 2022

Q4 2021 TRULICITY SALES INCREASED 25%

Millions

U.S. sales increased 25%
International sales increased 28%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average
Note: TRx data is representative of the injectable GLP-1 market

Q4 2021 TALTZ SALES INCREASED 31%

Millions

U.S. sales increased 36%
International sales increased 18%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average
Note: TRx data is representative of the full molecule market

Q4 2021 JARDIANCE SALES INCREASED 38%

Millions

U.S. sales increased 43%
International sales increased 31%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average
Note: Jardiance is part of the Boehringer Ingelheim and Lilly Alliance

Q4 2021 VERZENIO SALES INCREASED 43%

Millions

U.S. sales increased 34%
International sales increased 62%

U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average
Note: Q2 2020 IQVIA data was impacted by an addition of data for Verzenio

Q4 2021 CYRAMZA SALES DECREASED 5%

Millions

U.S. sales decreased 12%
International sales decreased 1%

Sales by Major Geography



Q4 2021 OLUMIANT SALES WERE $306 MILLION

Millions

U.S. sales were $88 million
International sales were $218 million



- Launched in the U.S. in July 2018
- Q4 sales driven by the U.S., Japan and Germany
- Growth largely driven by the utilization for the treatment of hospitalized patients with COVID-19
- Contributed ~150bps to Q4 WW volume growth

Q4 2021 EMGALITY SALES WERE $161 MILLION

Millions

U.S. sales were $121 million
International sales were $40 million



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average

Q4 2021 TYVYT SALES WERE $78 MILLION IN CHINA

Millions



- Launched in China in Q1 2019
- Part of Lilly collaboration with Innovent
- Contributed ~60bps to Q4 WW volume growth
- Q4 sales decline due to the one-time impact of 2022 NRDL price reductions on inventory already in the channel

Q4 2021 HUMALOG SALES DECREASED 16%

Millions

U.S. sales decreased 25%
International sales decreased 4%

U.S. TRx SOM



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average

Q4 2021 BASAGLAR SALES DECREASED 14%

Millions

U.S. sales decreased 19%
International sales decreased 1%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data December 24, 2021; RA = rolling average
Note: Basaglar is part of the Boehringer Ingelheim and Lilly Alliance

SELECT TRIALS – DONANEMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03367403	Alzheimer Disease	A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)	2	266	Change from Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score	Dec 2020	Nov 2021
NCT05108922	Alzheimer Disease	A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)	3	200	Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on donanemab versus aducanumab	Jun 2022	Jun 2023
NCT04437511	Alzheimer Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1800	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2023	Aug 2025
NCT04640077	Alzheimer Disease	A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)	2	100	Part A: Correlation between VTC and on-site assessment for PAIR 1 for Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)	May 2023	Oct 2023
NCT05026866	Alzheimer Disease	A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	3300	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Sep 2027	Nov 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – IMLUNESTRANT

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	800	Progression Free Survival (PFS)	Jun 2023	Sep 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – JARDIANCE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03594110[1]	Chronic Kidney Disease	EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)	3	6609	Composite primary outcome: Time to first occurrence of (i) kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m^2, renal death, or a sustained decline of ≥40% in eGFR from randomization) or (ii) Cardiovascular death	Nov 2022	Dec 2022
NCT04509674	Myocardial Infarction	EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)	3	5000	Composite of time to first heart failure hospitalisation or all-cause mortality	Mar 2023	Mar 2023

In collaboration with Boehringer Ingelheim

[1] Also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 25, 2022

SELECT TRIALS – LEBRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04146363	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)	1	240	Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Jun 2021	May 2022
NCT04178967	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)	3	400	Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Jul 2021	Jun 2022
NCT04250350	Atopic Dermatitis	Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)	3	400	Percentage of Participants Discontinued from Study Treatment Due to Adverse Events	Apr 2022	Jul 2022
NCT04760314	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)	3	200	Percentage of Participants with an Investigators Global Assessment (IGA) score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16	Jul 2022	Jan 2023
NCT04626297	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)	3	280	Percentage of Participants who Develop a Booster Response to Tetanus Toxoid 4 Weeks after Vaccine Administration	Aug 2022	Oct 2022
NCT04392154	Atopic Dermatitis	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	3	240	Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit	May 2024	May 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – LYUMJEV

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03952130	Type 1 Diabetes	A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes	3	350	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2022	Jan 2022
NCT04605991	Type 2 Diabetes	A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)	3	167	Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 milligrams/deciliter (mg/dL) (3.9-10.0 millimoles/Liter [mmol/L]) (both inclusive) during Daytime Period with 14 Days of CGM Use	Feb 2022	Feb 2022

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, December 17, 2021

SELECT TRIALS – MIRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03556202	Psoriasis	A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)	3	1816	Percentage of Participants with a Static Physician's Global Assessment Among Those who Entered the Study with a sPGA of 0,1(sPGA) of (0,1)	Jan 2022	Jan 2022
NCT03926130	Crohn's Disease	A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)	3	1150	Percentage of Participants Achieving Endoscopic Response	Dec 2023	Apr 2024
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Jan 2025	Apr 2027
NCT03518086	Ulcerative Colitis	An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)	3	1160	Percentage of Participants in Clinical Remission	Jan 2021	Oct 2022
NCT03524092	Ulcerative Colitis	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)	3	1044	Percentage of Participants in Clinical Remission	Nov 2021	Aug 2023
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	3	960	Percentage of Participants in Clinical Remission	Aug 2023	Jul 2025
NCT04844606	Ulcerative Colitis	A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)	3	185	Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission	Sep 2025	Sep 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – OLUMIANT

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899259	Alopecia Areata	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)	3	476	Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤20	Jan 2021	May 2024
NCT03570749	Alopecia Areata	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)	2|3	725	Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤20	Feb 2021	Jun 2024
NCT05074420	COVID-19	A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)	3	24	Pharmacokinetics (PK): Area Under Concentration Curve (AUC) of Baricitinib	July 2022	Aug 2022

In collaboration with Incyte

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – PIRTOBRUTINIB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04849416	Chronic Lymphocytic Leukemia	A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)	2	126	Overall Response Rate (ORR)	Sep 2022	Apr 2025
NCT03740529	Chronic Lymphocytic Leukemia	A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL	1|2	860	Maximum Tolerated Dose (MTD)	Jul 2023	Oct 2023
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	250	To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)	Jan 2024	Jun 2024
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	250	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Nov 2024	Jul 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2025	Jan 2027
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Aug 2024	Feb 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 14, 2022

SELECT TRIALS – RETEVMO

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899792	Medullary Thyroid Cancer	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)	1|2	100	To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)	Mar 2023	Mar 2024
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	400	Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)	May 2024	Nov 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1|2	989	Phase 1: MTD	Nov 2022	Nov 2023
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	250	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)	Jan 2023	Aug 2025
NCT04819100	Non-Small Cell Lung Cancer	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	170	Event-Free Survival (EFS)	Aug 2028	Nov 2032
NCT04280081	Solid Tumor	A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)	2	75	Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee	Mar 2021	Nov 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2021

SELECT TRIALS – SOLANEZUMAB

Study	Indication	Title	Phase	Patients	Primary Outcome*	Primary Completion	Completion
NCT02008357[1]	Cognition Disorders	Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)	3	1150	Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)	Dec 2022	Jun 2023

[1] Also lists Alzheimer's Therapeutic Research Institute

* Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, October 20, 2021

SELECT TRIALS – TIRZEPATIDE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04166773	Nonalcoholic Steatohepatitis	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (SYNERGY-NASH)	2	196	Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology	Nov 2023	Dec 2023
NCT04184622	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)	3	2539	Percent Change from Baseline in Body Weight	Apr 2022	May 2024
NCT05024032	Obesity	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	3	210	Mean Percent Change from Randomization in Body Weight	Nov 2022	Dec 2022
NCT04657003	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)	3	900	Percent Change from Randomization in Body Weight	Mar 2023	Apr 2023
NCT04660643	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4)	3	750	Percent Change from Randomization (Week 36) in Body Weight	Apr 2023	May 2023
NCT04657016	Obesity	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3)	3	800	Percent Change from Randomization in Body Weight	May 2023	Jun 2023
NCT04844918	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease (SURMOUNT-J)	3	261	Percentage of Participants who Achieve ≥5% Body Weight Reduction	Jul 2023	Jul 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – TIRZEPATIDE (CONT.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04537923	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)	3	1182	Change from Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses)	Oct 2022	Nov 2022
NCT04255433	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)	3	12500	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Oct 2024	Oct 2024
NCT04847557	HFpEF	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)	3	700	A Hierarchical Composite of All-Cause Mortality, Heart Failure Events, 6-minute Walk Test Distance (6MWD) and Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) Category	Nov 2023	Nov 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – VERZENIO

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease Free Survival (IDFS)	Mar 2020	Jun 2029
NCT05169567	Breast Cancer	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	350	Progression-Free Survival (PFS)	Aug 2023	Feb 2026
NCT03706365	Prostate Cancer	A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)	2|3	350	Radiographic Progression Free Survival (rPFS)	Dec 2023	Jun 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 24, 2022

SELECT TRIALS – EARLY PHASE DIABETES

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GLP-1R NPA	NCT05048719	Type 2 Diabetes	A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus	2	370	Change from Baseline in Hemoglobin A1c (HbA1c) in LY3502970 and Placebo	May 2022	Aug 2022
GGG Tri-Agonist	NCT04867785	Type 2 Diabetes	A Study of LY3437943 in Participants With Type 2 Diabetes	2	300	Change from Baseline in Hemoglobin A1c (HbA1c)	Jun 2022	Sep 2022
GGG Tri-Agonist	NCT04881760	Obesity	A Study of LY3437943 in Participants Who Have Obesity or Are Overweight	2	494	Mean Percent Change in Body Weight	Jun 2022	Nov 2022
GLP-1R NPA	NCT05051579	Obesity	A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities	2	270	Percent Change From Baseline in Body Weight	Sep 2022	Sep 2022
LP(a) Disrupter Inhibitor	NCT05038787	Healthy	A Study of LY3473329 in Healthy Japanese Participants	1	24	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jan 2022	Apr 2022
ANGPTL-siRNA	NCT04644809	Dyslipidemias	A Study of LY3561774 in Participants With Dyslipidemia	1	74	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	May 2022	May 2022

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 25, 2022

SELECT TRIALS – EARLY PHASE DIABETES (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GLP-1R NPA	NCT05086445	Type 2 Diabetes	A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus	1	65	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jun 2022	Jun 2022
Basal Insulin - FC	NCT04957914	Type 2 Diabetes	A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus	1	50	Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus	Jul 2022	Jul 2022
Relaxin-LA	NCT04768855	Healthy	A Study of LY3540378 in Healthy Participants	1	132	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2022	Aug 2022
LP(a)-siRNA	NCT04914546	Healthy	A Study of LY3819469 in Healthy Participants	1	66	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2022	Oct 2022
NRG4 Agonist	NCT04840914	HFrEF	A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction	1	50	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2023	Jul 2023

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – EARLY PHASE IMMUNOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
PD-1 Mab Agonist	NCT04634253	Rheumatoid Arthritis	A Study of LY3462817 in Participants With Rheumatoid Arthritis	2	80	Change from Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP)	Jan 2022	Jun 2022
CXCR1/2L mAb	NCT04493502	Hidradenitis Suppurativa	A Study of LY3041658 in Adults With Hidradenitis Suppurativa	2	52	Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR)	Apr 2022	Nov 2022
IL-2 CONJUGATE[1]	NCT04433585	Systemic Lupus Erythematosus	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	2	280	Percentage of Participants who Achieve a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score	Nov 2022	Feb 2023
BTLA MAB Agonist	NCT05123586	Systemic Lupus Erythematosus	A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus	2	90	Percentage of Participants with Arthritis and/or Rash at Baseline Who Achieve Remission of Arthritis and/or Rash	Apr 2023	Aug 2023
IL-2 CONJUGATE[1]	NCT04677179	Ulcerative Colitis	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	2	200	Percentage of Participants in Clinical Remission	Nov 2023	Oct 2024

[1] Also lists Nektar Therapeutics

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – EARLY PHASE IMMUNOLOGY (CONT.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
IL-2 CONJUGATE[1]	NCT04081350	Atopic Dermatitis	A Study of LY3471851 in Participants With Eczema	1	40	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2022	Aug 2022
BTLA MAB Agonist	NCT04975295	Psoriasis	A Study of LY3361237 in Participants With Psoriasis	1	24	Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2022	Oct 2022
CD19 Antibody	NCT05042310	Healthy	A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants	1	84	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2022	Nov 2022

[1] Also lists Nektar Therapeutics

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – EARLY PHASE NEURODEGENERATION

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
O-GlcNAcase Inh.	NCT05063539	Alzheimer Disease	A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease	2	330	Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2024	Jun 2024
N3PG Aß MAB	NCT04451408	Alzheimer Disease	A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants	1	120	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Sep 2023	Sep 2023
GBA1 Gene Therapy	NCT04127578	Parkinson Disease	Phase 1/2a Clinical Trial of PR001 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	12	Number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Jun 2027	Jun 2027
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1|2	15	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Sep 2027	Sep 2027
GBA1 Gene Therapy	NCT04411654	Gaucher Disease, Type 2	Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)	1|2	15	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation	Sep 2028	Sep 2028

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 19, 2022

SELECT TRIALS – EARLY PHASE ONCOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
IDH1 Inhibitor	NCT04603001	Acute Myeloid Leukemia (AML)	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	1	220	To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)	Feb 2023	Sep 2023
IDH1 Inhibitor	NCT04521686	Cholangiocarcinoma	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	1	180	Recommended Phase 2 dose (RP2D)	Feb 2023	Sep 2023
KRAS G12C	NCT04956640	NSCLC and CRC	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1	260	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Oct 2023	Oct 2023
BCL2	NCT05024045	Chronic Lymphocytic Leukemia, B-Cell	Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	1	286	Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338	Apr 2024	Apr 2024
Aur A Kinase Inhibitor[1]	NCT04106219	Neuroblastoma	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	1	71	Number of Participants with Dose Limiting Toxicities (DLTs)	Apr 2024	Apr 2025

[1] Also lists New Approaches to Neuroblastoma Therapy Consortium (NANT) and Innovative Therapies for Children with Cancer in Europe (ITCC)

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 25, 2022

SELECT TRIALS – EARLY PHASE PAIN

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
TRPA1 Antagonist	NCT05080660	Osteoarthritis	Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis	2	150	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jun 2022	Jun 2022
TRPA1 Antagonist	NCT05086289	Chronic Low-back Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain	2	150	Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jul 2022	Jul 2022
TRPA1 Antagonist	NCT05177094	Diabetic Peripheral Neuropathic Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain	2	150	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Sep 2022	Sep 2022
PACAP38 MAB	NCT04498910	Migraine	A Study of LY3451838 in Participants With Migraine	2	120	Change from Baseline in the Number of Monthly Migraine Headache Days	Sep 2022	Sep 2022
SSTR4 Agonist	NCT04707157	Diabetic Peripheral Neuropathic Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain	2	150	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Feb 2024	Feb 2024
SSTR4 Agonist	NCT04874636	Chronic Low-back Pain	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain	1	200	Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Feb 2022	Feb 2022

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 21, 2022


Lilly